The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCreo Medical Regulatory News (CREO)

Share Price Information for Creo Medical (CREO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 35.25
Bid: 35.00
Ask: 35.50
Change: 0.00 (0.00%)
Spread: 0.50 (1.429%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 35.25
CREO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Treasury Building Refinance

4 Aug 2009 07:00

RNS Number : 7945W
China Real Estate Opportunities PLC
04 August 2009
 



4 August 2009

China Real Estate Opportunities plc

Treasury Building Refinance

China Real Estate Opportunities plc ("CREO" or the "Company") is pleased to announce that terms have been agreed and credit approval received for a multi-currency five year loan facility equivalent to ₤26.6 million (based on current exchange rates) with the Industrial and Commercial Bank of China (ICBC). 

This facility will refinance the existing 18.8 million and RMB97 million loan CREO has with Credit Suisse in regard to the Treasury Building Shanghai which expires in March 2010. It is expected that this transaction will be completed by October 2009. Under the approved terms, CREO will benefit from approximately ₤2 million of increased liquidity, subject to the exchange rates prevailing at the date of the refinance, as the principal amount of the ICBC facility exceeds the existing Credit Suisse loan. In addition, the interest cost on this loan facility will be reduced by approximately ₤200,000 per annum, representing a 15% saving, based on the current 3 year London Interbank Offer Rate (LIBOR), when compared to the terms of the current loan.

Ray Horney, CREO Chairman commented, "I am most encouraged that credit approval has been received for the refinancing of the Treasury Building well ahead of the expiry of the current loan, as this provides confidence that progress can be made in relation to CREO's later refinancings.

 

The Company is developing strong relationships with Chinese banks and the Company's ability to secure additional funding and to extend the term of the debt facility further demonstrates the high quality, resilient nature of the Company's assets"

Contact:

CREO

Ray Horney, Chairman

Tel: + 44 (0) 1273 775 225 

Sarah Moriarty, Investor Relations

Tel: + 353 1 618 9455

Matrix Corporate Capital LLP

Paul Fincham, Rob Naylor

Tel: + 44 (0) 20 3206 7000

Davy

Des Carville

Tel: +353 1 679 6363

Bankside Consultants 

Simon Rothschild, Oliver Winters 

Tel: 44 (0) 20 7367 8888

Murray Consultants 

Ed Micheau

Tel: + 353 1 498 0300

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEXLFBKVBXBBE
Date   Source Headline
21st Feb 202310:29 amRNSHolding(s) in Company
17th Feb 20232:05 pmRNSSecond Price Monitoring Extn
17th Feb 20232:00 pmRNSPrice Monitoring Extension
17th Feb 202312:10 pmRNSLaunch of Open Offer and Posting of Circular
16th Feb 20236:04 pmRNSResult of Placing and Subscription
16th Feb 20239:05 amRNSSecond Price Monitoring Extn
16th Feb 20239:00 amRNSPrice Monitoring Extension
16th Feb 20237:00 amRNSPlacing and Subscription to raise a minimum £25m
15th Feb 202311:05 amRNSSecond Price Monitoring Extn
15th Feb 202311:00 amRNSPrice Monitoring Extension
30th Jan 20238:51 amRNSAward of Shares under Share Incentive Plan
23rd Jan 202311:47 amEQSCreo Medical (CREO): Progressing on all fronts
18th Jan 20232:05 pmRNSSecond Price Monitoring Extn
18th Jan 20232:00 pmRNSPrice Monitoring Extension
11th Jan 20237:00 amRNSFY 2022 Trading Update
16th Dec 20222:05 pmRNSSecond Price Monitoring Extn
16th Dec 20222:00 pmRNSPrice Monitoring Extension
1st Dec 20222:12 pmRNSHolding(s) in Company
24th Oct 20227:00 amRNSKamaptive Licence and Royalty Agreement with CMR
30th Sep 20227:00 amRNSTotal Voting Rights
23rd Sep 20227:00 amRNSExercise of Options
23rd Sep 20227:00 amRNSExercise of Options
22nd Sep 20227:00 amRNSChris Hancock elected as a Fellow of Royal Academy
9th Sep 20227:00 amRNSHalf-year Report
5th Sep 20227:00 amRNSNotice of Results
31st Aug 20227:00 amRNSTotal Voting Rights
8th Aug 20227:00 amRNSLTIP Awards and PDMR Dealing
4th Aug 20227:00 amRNSExercise of Options
3rd Aug 20227:00 amRNSH1 2022 Trading Update
2nd Aug 20227:00 amRNSAward of Shares under Share Incentive Plan
28th Jun 202212:33 pmRNSResult of AGM
28th Jun 20227:00 amRNSAGM Statement
27th May 20227:00 amRNSDirector/PDMR Shareholding
26th May 20227:00 amRNSPosting of 2021 Annual Report and Accounts
23rd May 20227:01 amRNSFinal Results
23rd May 20227:00 amRNSCollaboration agreement with Intuitive
18th May 20223:22 pmRNSHolding(s) in Company
17th May 20227:00 amRNSNotice of Results
28th Apr 20227:00 amRNSTrading update and notice of results
20th Apr 20227:00 amRNSOpening of Singapore regional hub
5th Apr 20227:00 amRNSCTO wins Technology Innovator of the Year Award
16th Mar 20227:00 amRNSAlbyn Medical earn out update
28th Feb 20227:00 amRNSTotal Voting Rights
7th Feb 20227:00 amRNSPresentation at Growth and Innovation Forum 2022
4th Feb 20227:00 amRNSAward of Shares under Share Incentive Plan
3rd Feb 20224:41 pmRNSSecond Price Monitoring Extn
3rd Feb 20224:35 pmRNSPrice Monitoring Extension
3rd Feb 20227:00 amRNSTrading update
24th Jan 20227:00 amRNSLicensing & Partnership update
31st Dec 20217:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.